Barriers for retinal gene therapy: separating fact from fiction

Area of Science:

• Ophthalmology
• Gene Therapy
• Molecular Biology

Background:

• Adeno-associated virus (AAV) is widely used in retinal gene therapy but has limitations including immunogenicity, insertional mutagenesis, and limited cloning capacity.
• Lentivirus vectors are being explored for ocular gene therapy, but their efficiency in transducing photoreceptor cells is not well-established.
• Adenovirus vectors have been used in the only two completed ocular gene therapy clinical trials with no serious adverse events.

Purpose of the Study:

• To evaluate the potential of Helper-dependent Adenovirus (Hd-Ad) vectors as a gene therapy tool for retinal degenerative diseases.
• To compare the efficacy and safety of Hd-Ad vectors with AAV and lentivirus vectors for ocular gene therapy.

Main Methods:

• Review of existing preclinical and clinical data on viral vectors for retinal gene therapy.
• Analysis of the properties of Hd-Ad vectors, including transgene expression duration and immunogenicity.
• Comparison of the advantages and disadvantages of AAV, lentivirus, and adenovirus vectors in the context of ocular gene therapy.

Main Results:

• AAV vectors exhibit limitations such as inflammatory responses, insertional mutagenesis, and restricted cargo size.
• Adenovirus vectors have demonstrated a good safety profile in clinical trials, with no serious adverse events reported.
• Helper-dependent Adenovirus (Hd-Ad) vectors have shown the ability to express transgenes in ocular tissues for over one year.

Conclusions:

• Helper-dependent Adenovirus (Hd-Ad) vectors possess favorable characteristics for retinal gene therapy, including long-term transgene expression.
• Hd-Ad vectors represent a promising alternative to AAV and lentivirus vectors for treating retinal degenerative diseases.
• Further investigation into Hd-Ad vectors is warranted to fully establish their role in the retinal gene therapy armamentarium.